澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

MESOBLAST LTD

2.310

-0.040-1.70%

成交量：91.04万

成交额：212.34万

市值：29.81亿

市盈率：-19.26

高：2.360

开：2.350

低：2.310

收：2.350

52周最高：3.310

52周最低：1.515

股本：12.90亿

流通股本：7.86亿

量比：0.89

换手率：0.12%

股息：- -

股息率：- -

每股收益(TTM):-0.120

每股收益(LYR):-0.120

净资产收益率：-18.95%

总资产收益率：-5.37%

市净率：3.52

市盈率(LYR):-19.27

数据加载中...

总览公司新闻资讯公告

FDA确认Rexlemestrocel-L在疼痛强度上展现积极效果，12个月背痛减轻数据支持产品疗效

独立研究在美国血液学会年会上提出，Remestemcel-L在治疗SR-Agvhd的临床效果上优于Ruxolitinib

异动解读 | Mesoblast股价盘中大涨6.72%，预计季度收入超3000万美元

Mesoblast Limited - 预计2025年12月31日季度毛收入超过3000万美元，来自Ryoncil的销售

Mesoblast宣布James M. O’Brien被任命为首席财务官

新闻稿：詹姆斯·M·奥布莱恩被任命为美莎比信托首席财务官

BUZZ-奥布莱恩出任美国分部财务总监，Mesoblast 的澳大利亚股票攀升

Mesoblast将于下月与FDA会谈讨论Rexlemestrocel-L和阿片类药物戒断

Mesoblast将于下月与FDA会面讨论Rexlemestrocel-L和药物戒断

Mesoblast迎来里程碑年份：首获FDA产品批准并成功商业化推出Ryoncil®

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/MSB.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.31,"timestamp":1771898715026,"preClose":2.35,"halted":0,"volume":910396,"delay":0,"changeRate":-0.017021276595744695,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1290302187,"eps":-0.11994215555618566,"marketStatus":"交易中","change":-0.04,"latestTime":"02-24 13:05:26 AEDT","open":2.35,"high":2.36,"low":2.31,"amount":2123428,"amplitude":0.021277,"askPrice":2.32,"askSize":53838,"bidPrice":2.31,"bidSize":69861,"shortable":3,"etf":0,"ttmEps":-0.11994215555618566,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1771909200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":2.35,"openAndCloseTimeList":[[1771887600000,1771909200000]],"volumeRatio":0.890779,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-5.37%","roe":"-18.95%","lyrEps":-0.119898,"volumeRatio":0.890779,"shares":1290302187,"dividePrice":0,"high":2.36,"amplitude":0.021277,"preClose":2.35,"low":2.31,"week52Low":1.515,"pbRate":"3.52","psRate":"122.24","week52High":3.31,"institutionHeld":0,"latestPrice":2.31,"committee":0.129532,"eps":-0.11994215555618566,"divideRate":0,"volume":910396,"delay":0,"ttmEps":-0.11994215555618566,"open":2.35,"prevYearClose":2.72,"prevWeekClose":2.41,"prevMonthClose":2.53,"prevQuarterClose":2.72,"fiveDayClose":2.41,"twentyDayClose":2.69,"sixtyDayClose":2.72,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1118834527","title":"FDA确认Rexlemestrocel-L在疼痛强度上展现积极效果，12个月背痛减轻数据支持产品疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1118834527","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118834527?lang=zh_cn&edition=fundamental","pubTime":"2026-01-19 08:02","pubTimestamp":1768780936,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式认可Rexlemestrocel-L在缓解疼痛强度方面表现出显著优势。最新数据显示，该疗法在12个月内持续减轻背痛的效果，进一步验证了其临床有效性。这一进展为MESOBLAST LTD旗下产品的应用前景提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","MSB.AU","BK7501","BK7508"],"gpt_icon":0},{"id":"1100916668","title":"独立研究在美国血液学会年会上提出，Remestemcel-L在治疗SR-Agvhd的临床效果上优于Ruxolitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=1100916668","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100916668?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 07:26","pubTimestamp":1765495606,"startTime":"0","endTime":"0","summary":"独立研究在美国血液学会年会上提出，Remestemcel-L在治疗SR-Agvhd的临床效果上优于Ruxolitinib","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","BK7508","MSB.AU"],"gpt_icon":0},{"id":"1115028816","title":"异动解读 | Mesoblast股价盘中大涨6.72%，预计季度收入超3000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115028816","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115028816?lang=zh_cn&edition=fundamental","pubTime":"2025-11-26 07:03","pubTimestamp":1764111792,"startTime":"0","endTime":"0","summary":"澳大利亚生物技术公司Mesoblast Limited今日盘中股价大涨6.72%，引起投资者广泛关注。此轮涨势主要源于公司发布的积极财务预期。Mesoblast预计截至2025年12月31日的季度毛收入将超过3000万美元，这一收入主要来自其重磅产品Ryoncil的销售。Ryoncil是Mesoblast的主打产品，用于治疗急性移植物抗宿主病。该产品的强劲销售表现不仅直接提升了公司的财务状况，也增强了投资者对Mesoblast长期发展前景的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MSB.AU"],"gpt_icon":0},{"id":"1109683405","title":"Mesoblast Limited - 预计2025年12月31日季度毛收入超过3000万美元，来自Ryoncil的销售","url":"https://stock-news.laohu8.com/highlight/detail?id=1109683405","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109683405?lang=zh_cn&edition=fundamental","pubTime":"2025-11-25 22:45","pubTimestamp":1764081909,"startTime":"0","endTime":"0","summary":"Mesoblast Limited - 预计2025年12月31日季度毛收入超过3000万美元，来自Ryoncil的销售","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","MSB.AU","BK7508","BK7501","MESO","BK4139"],"gpt_icon":0},{"id":"1182398223","title":"Mesoblast宣布James M. O’Brien被任命为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1182398223","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182398223?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 16:14","pubTimestamp":1763367269,"startTime":"0","endTime":"0","summary":"11月17日 - Mesoblast Ltd：James M. O’Brien被任命为Mesoblast的首席财务官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","MSB.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"1195991725","title":"新闻稿：詹姆斯·M·奥布莱恩被任命为美莎比信托首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1195991725","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195991725?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 14:56","pubTimestamp":1763362561,"startTime":"0","endTime":"0","summary":"纽约，2025年11月17日-- 美莎比信托，全球领先的用于治疗炎症性疾病的同种异体细胞药物公司，今天宣布，在公司向一个完全整合的商业组织转型之际，任命詹姆斯·M·奥布莱恩为其美国首席财务官。詹姆斯在财务管理和规划的各个方面拥有丰富经验，职业生涯的大部分时间都在生命科学、生物技术和制药行业的跨国公私公司中度过。本发布已获首席执行官授权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4139","BK4022","BK4575","CFO","BMS","BK4150","MSB","BK7067","BK4006","BK7501","BK7508","MSB.AU","R","MESO","MSC"],"gpt_icon":0},{"id":"2584924916","title":"BUZZ-奥布莱恩出任美国分部财务总监，Mesoblast 的澳大利亚股票攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2584924916","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584924916?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 09:11","pubTimestamp":1763341883,"startTime":"0","endTime":"0","summary":"11月17日 - ** 在澳大利亚证券交易所上市的炎症性疾病药物生产商Mesoblast MSB.AX的股价上涨3.6%，达到2.3澳元，结束了连续两个交易日的下跌。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nL4T3WT01H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","BK4007","CGTX","BK7508","MSB.AU"],"gpt_icon":0},{"id":"1116191251","title":"Mesoblast将于下月与FDA会谈讨论Rexlemestrocel-L和阿片类药物戒断","url":"https://stock-news.laohu8.com/highlight/detail?id=1116191251","media":"投资观察","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116191251?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 09:45","pubTimestamp":1762307124,"startTime":"0","endTime":"0","summary":"11月5日（路透社） - Mesoblast Ltd：*MESOBLAST将于下月与FDA会面，讨论Rexlemestrocel-L和阿片类药物戒断* 进一步公司报道：MSB.AX","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7501","BK7508","BK7067"],"gpt_icon":0},{"id":"1199521939","title":"Mesoblast将于下月与FDA会面讨论Rexlemestrocel-L和药物戒断","url":"https://stock-news.laohu8.com/highlight/detail?id=1199521939","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199521939?lang=zh_cn&edition=fundamental","pubTime":"2025-11-05 06:59","pubTimestamp":1762297168,"startTime":"0","endTime":"0","summary":"Mesoblast将于下月与FDA会面，讨论Rexlemestrocel-L和药物戒断的相关事宜。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","BK7501","BK7067","MSB.AU","BK7508","BK4139"],"gpt_icon":0},{"id":"1114267169","title":"Mesoblast迎来里程碑年份：首获FDA产品批准并成功商业化推出Ryoncil®","url":"https://stock-news.laohu8.com/highlight/detail?id=1114267169","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114267169?lang=zh_cn&edition=fundamental","pubTime":"2025-08-29 08:25","pubTimestamp":1756427111,"startTime":"0","endTime":"0","summary":"Mesoblast迎来里程碑年份：首获FDA产品批准并成功商业化推出Ryoncil®","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7508","BK7501","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}